{"id":294,"date":"2024-05-17T22:00:00","date_gmt":"2024-05-17T22:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=294"},"modified":"2025-09-10T13:10:41","modified_gmt":"2025-09-10T13:10:41","slug":"china-bd-2024-medshine-and-erasca-enters-a-license-on-selective-kras-inhibitor-eras-4001","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2024\/294.html","title":{"rendered":"[China BD 2024] Medshine and Erasca enters a License on selective KRAS inhibitor ERAS-4001"},"content":{"rendered":"\n<p>Announced Date: 2024-05-16 (May 16, 2024)<\/p>\n\n\n\n<p>Asset Name: ERAS-4001<\/p>\n\n\n\n<p>Licensor (Seller): Medshine Discovery (China)<\/p>\n\n\n\n<p>Licensee (Buyer): Erasca (US)<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality: Small Molecule<\/p>\n\n\n\n<p>Asset Target:  selective KRAS inhibitor<\/p>\n\n\n\n<p>Potential Indication: oncology diseases<\/p>\n\n\n\n<p>Current Stage: preclinical&nbsp;<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority:<\/p>\n\n\n\n<p>Erasca will be granted an exclusive license to research, develop and commercialize ERAS-4001 worldwide.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Payment Detail:<\/p>\n\n\n\n<p>One-time upfront cash payment of\u00a0$10.0 million, <\/p>\n\n\n\n<p>Development, regulatory, and commercialization milestones up to\u00a0$160.0 million. <\/p>\n\n\n\n<p>Low-single digit percentage royalty.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p><a href=\"https:\/\/investors.erasca.com\/news-releases\/news-release-details\/erasca-announces-strategic-licensing-ras-targeting-franchise\">Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise \u2013 Erasca<\/a><\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Note:<\/p>\n\n\n\n<p>Chinese Name of \u201cMedshine Discovery \u201c\uff0c\u660e\u5fb7\u65b0\u836f<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2024-05-16 (May 16, 2024) Asset Name: ERAS-4001 Licensor (Seller): Medshine Discovery (China) Licensee (Buyer): &hellip; <a title=\"[China BD 2024] Medshine and Erasca enters a License on selective KRAS inhibitor ERAS-4001\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2024\/294.html\"><span class=\"screen-reader-text\">[China BD 2024] Medshine and Erasca enters a License on selective KRAS inhibitor ERAS-4001<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-294","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/294","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=294"}],"version-history":[{"count":1,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/294\/revisions"}],"predecessor-version":[{"id":296,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/294\/revisions\/296"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=294"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=294"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=294"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}